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Abstract
Introduction: Reversible cerebral vasoconstriction syndrome presents with thunderclap headaches accompanied
by mild neurologic deficits and is characterized by multifocal narrowing of the cerebral arteries that resolves over
days to weeks. This syndrome may be idiopathic or occur in special contexts, most often involving adrenergic or
serotonergic overactivity. To the best of our knowledge, reversible cerebral vasoconstriction syndrome has not
previously been reported in association with Hydroxycut use in the literature.
Case Presentation: We report the case of a 65-year-old Caucasian woman on longstanding citalopram who
developed reversible cerebral vasoconstriction syndrome two weeks after beginning to take the weight-loss
supplement Hydroxycut.
Conclusion: There are sparse data about the safety of herbal supplements such as Hydroxycut, even though the
Food and Drug Administration has banned some herbal ingredients, such as ephedra, that were in this preparation
in the past. This case highlights the importance of considering herbal supplements and potential drug interactions
in the genesis of otherwise unexplained reversible cerebral vasoconstriction syndrome.
Introduction
Reversible cerebral vasoconstriction syndrome (RCVS) is
the term for a group of rare syndromes characterized by
multifocal narrowing of the cerebral arteries that resolves
over the course of days to weeks [1]. Patients present with
sudden, severe “thunderclap” headaches that may be
accompanied by neurologic deficits [1]. Clinical situations
associated with the development of RCVS include preg-
nancy or the postpartum period and various medications
and illicit drugs [2]. RCVS is diagnosed on the basis of
this clinical presentation, exclusion of other causes of
thunderclap headache such as subarachnoid hemorrhage
and cerebral vasculitis by cerebrospinal fluid analysis,
documentation of multifocal vasoconstriction of the cere-
bral arteries by angiography, and of reversibility of the
vasoconstriction within 12 weeks of onset, although there
may be permanent neurologic injury if stroke occurs sec-
ondary to vasospasm [1]. Treatment has included calcium
channel blockers [3,4] or magnesium [5], and disconti-
nuation of potential triggers for RCVS, particularly adre-
nergic or serotonergic compounds.
We report the case of a patient on longstanding citalo-
pram who developed RCVS two weeks after beginning to
take the weight-loss supplement Hydroxycut, and we
review the literature identifying factors associated with
development of RCVS.
Case Presentation
A 65-year-old Caucasian woman presented to her local
hospital with sudden-onset, bifrontal, pounding headache
described as “getting hit in the head with an axe.” The
headache was the worst of her life and did not improve
after she took acetaminophen, caffeine, and butalbital.
There was hyperacusis, photophobia and nausea. Noncon-
trast head computed tomography (CT) and brain magnetic
resonance imaging (MRI) at the time of admission were
normal and she was treated with prednisone for presumed
intractable migraine. Aside from a similar but milder head-
ache one week prior to her current presentation, she
reported only a sparse past history of migraines that ceased
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or strokes. She had hyperlipidemia treated with simvastatin
40 mg daily, lumbar spinal compression fractures, multiple
miscarriages and depression that had been treated for sev-
eral years with citalopram 20 mg daily. On further ques-
tioning, our patient reported taking the weight-loss
supplement Hydroxycut beginning two weeks prior to her
thunderclap headache. On admission, her body mass index
was 22.3, and she was normotensive on lisinopril 10 mg
daily. She had not previously been on lisinopril, which was
presumably initiated at the outside hospital for prednisone-
induced hypertension. We held the lisinopril for the dura-
tion of her hospitalization given her normal to low blood
pressures. Her fasting lipid panel revealed cholesterol 223
mg/dL, triglycerides 141 mg/dL, high density lipoprotein
61 mg/dL, low density lipoprotein 134 mg/dL, very low
density lipoprotein 28 mg/dL and lipoprotein(a) 6 mg/dL.
Two days after admission, she developed bilateral leg
weakness and left-sided visual disturbances that she
described as “blank lines.” A repeat MRI revealed areas
of restricted diffusion consistent with acute infarcts in
the bilateral anterior cerebral artery territories and in
her right occipital lobe (Figure 1). The following investi-
gations were unrevealing: hypercoagulability studies,
rheumatic and vasculitic screening labs, magnetic reso-
nance venography, transthoracic echocardiogram with
bubble contrast, and Holter monitoring. LA lumbar
puncture, performed while our patient was being treated
with prednisone, revealed 0 white blood cells (WBC), 48
red blood cells (RBC), cerebrospinal fluid (CSF) protein
27 mg/dL, glucose 81 mg/dL and no xanthochromia.
CT angiography (CTA) was obtained, which revealed
multifocal segmental cerebral artery vasoconstriction,
most prominent in the bilateral anterior and posterior
cerebral arteries (Figures 2A and 2B).
We made the diagnosis of RCVS and began treatment
with nimodipine 30 mg three times daily. Over the sub-
sequent days, her headache resolved and her vision and
leg weakness improved. Our patient’s blood pressures at
admission and prior to starting nimodipine were 92-
Figure 1 RVCS-related ischemic strokes. Diffusion-weighted MRI (A, B, C) and apparent diffusion coefficient maps (D, E, F) revealed lesions in
the right occipital lobe and bilateral anterior cerebral artery territories consistent with ischemic strokes.
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After beginning nimodipine for RCVS, her systolic
blood pressures ranged from the high 80s to low 100s
(mmHg). We administered intravenous fluid bolus as
needed to keep her systolic blood pressure above 90
mmHg, in an effort to balance maintaining adequate
cerebral perfusion while continuing nimodipine treat-
ment for RCVS. Our patient tolerated this well without
any clinical decline or symptomatic hypotension.
She was discharged on nimodipine and advised not to
take Hydroxycut and citalopram, which had been dis-
continued when a diagnosis of RCVS was first sus-
pected. At the time of discharge, her systolic blood
pressures remained in the 90s to low 100s mmHg.
Therefore, she was advised to measure her blood pres-
sure at home and take nimodipine only if systolic blood
pressure was over 100 mmHg. Following discharge, our
patient experienced no headaches and no recurrence of
her presenting symptoms. At a follow-up appointment,
she had no residual leg weakness and significant
improvement of her left visual field deficit, although she
reported that her vision had not returned to her base-
line. CTA performed six weeks after discharge showed
marked resolution of cerebral vasoconstriction, confirm-
ing the diagnosis of RCVS (Figures 2C and 2D).
Discussion
This case illustrates the cardinal features of RCVS: thun-
derclap headache, lack of subarachnoid hemorrhage by
CSF and radiographic analysis, ostensible exclusion of
cerebral vasculitis by CSF and systemic testing, and
angiographic demonstration of multifocal segmental cer-
ebral artery vasoconstriction that resolves with time or
calcium channel blocker treatment. It also exemplifies
ischemic strokes as complications of RCVS [6], empha-
sizing the delicate balance between maintenance of ade-
quate cerebral perfusion pressure to avoid watershed
infarcts while using calcium channel blockers to mitigate
against worsening vasoconstriction [2].
The other aspect of RCVS treatment is identification
and discontinuation of the potential triggers of RCVS.
The clinical settings for RCVS include pregnancy and
the postpartum state, serotonergic and sympathomi-
metic drugs and tumors, direct or neurosurgical trauma,
hypertension, primary headache disorders such as
migraine and other miscellaneous conditions such as
Figure 2 RCVS on computed tomography angiography. CTA obtained during hospitalization showed multifocal segmental vasoconstrictions
most prominent in the bilateral anterior (A) and posterior (B) cerebral arteries. Follow-up CTA six weeks after discharge revealed marked
resolution of cerebral artery vasoconstriction, shown here for anterior (C) and posterior (D) cerebral arteries.
Cvetanovich et al. Journal of Medical Case Reports 2011, 5:548
http://www.jmedicalcasereports.com/content/5/1/548
Page 3 of 5hypercalcemia and porphyria [1,2]. Regardless of etiol-
ogy, RCVS is thought to occur due to perturbation of
cerebral vascular tone [1].
Although amphetamine-related weight-loss supple-
ments and selective serotonin reuptake inhibitors
including citalopram have been associated with RCVS
[1,7-9], Hydroxycut has not previously been implicated.
It is impossible to prove causality, but the temporal rela-
tionship between the patient’s initiation of Hydroxycut
and development of RCVS and the rapid reversal of
symptoms and vasospasm following cessation implicate
the supplement as a contributing cause in this case.
Citalopram may have acted in concert with the newly-
initiated Hydroxycut to cause this patient’sR C V S ,
though the fact that she tolerated citalopram well for
several years before developing RCVS argues against the
antidepressant drug as the sole trigger.
Hydroxycut is among the most popular weight-loss
supplements with nine million units sold in 2008 in the
US alone [10] and, like most herbal supplements, con-
tains poorly characterized components whose side effect
profiles are ill-defined [11]. After Hydroxycut was intro-
duced in 2002, the first adverse events were probably
related to its ephedra component, which was banned by
the Food and Drug Administration (FDA) in 2004 for
causing severe cardiovascular, central nervous system
and hepatic toxicity [12]. Since the removal of ephedra
from Hydroxycut in 2004, published adverse events have
included numerous cases of hepatotoxicity [13], one
case of rhabdomyolysis [14] and one case of hyperten-
sive retinopathy [15]. In May 2009, the FDA warned the
public about Hydroxycut hepatotoxicity, prompting the
manufacturer to withdraw all Hydroxycut products [16].
Recently, a new Hydroxycut formulation has been
introduced, and it is this one that our patient with
RCVS was taking. Based on the tendency of sympatho-
mimetic agents to trigger RCVS, caffeine may have been
the ingredient responsible for RCVS as the usual daily
dose of Hydroxycut contains 400 mg of caffeine per day
[17], which is equivalent to four cups of coffee. Caffeine
is known to cause cerebral vasoconstriction [18],
although it has not been associated with RCVS. Other
components of the new Hydroxycut formulation may
have contributed, although to our knowledge none has
vasoconstrictive properties.
Conclusion
We report a case report of a patient on longstanding
citalopram who developed RCVS two weeks after begin-
ning to take the weight-loss supplement Hydroxycut.
Given the sparse data about the efficacy and safety of
herbal supplements such as Hydroxycut, it is advisable
to consider the potential roles of dietary supplements
and drug interactions in cases of otherwise unexplained
cerebrovascular disease.
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